Can immune cell clues predict transplant success in leukemia?

NCT ID NCT03921047

First seen Dec 18, 2025 · Last updated Jun 22, 2026 · Updated 30 times

Summary

This study tracks T-cell changes in 250 acute myeloid leukemia patients receiving a stem cell transplant. By analyzing blood samples with advanced gene sequencing, researchers hope to understand if the immune system plays a key role in recovery and complications. The goal is to find patterns that could predict graft-versus-host disease or relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • USC / Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better predict and manage complications like graft-versus-host disease or relapse after stem cell transplant for AML.

What could go wrong

This is an observational study, not a treatment trial. It will not directly improve outcomes for participants and may not lead to any new tests or therapies.

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.